CLINICAL TRIALS PROFILE FOR ZOLOFT

All Clinical Trials for ZOLOFT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000440 ↗	Sertraline and Naltrexone for Alcohol Dependence	Completed	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 2	1969-12-31	This study is a double-blind, placebo-controlled outpatient trial to improve, through the addition of sertraline (Zoloft), the abstinence and relapse rates in alcohol- dependent individuals currently taking naltrexone (Revia).
NCT00000446 ↗	Drug Treatment for Alcoholics With Post-Traumatic Stress Disorder	Completed	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 2	1969-12-31	This study will investigate the use of sertraline (Zoloft) to decrease alcohol consumption and crime-related post-traumatic stress disorder in those individuals with both disorders. This will be a 12-week, placebo-controlled, double-blind outpatient trial. All subjects will receive cognitive behavioral therapy in addition to a placebo or sertraline. Comprehensive evaluation will be done at study entry; treatment termination; and 6, 9, and 12 months after study entry.
NCT00000451 ↗	Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)	Completed	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 2	2003-01-01	This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study.
NCT00000451 ↗	Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)	Completed	Yale University	Phase 2	2003-01-01	This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study.
NCT00000458 ↗	Sertraline and Cognitive Therapy in Depressed Alcoholics	Completed	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 2	1969-12-31	This study will assess whether individuals treated with sertraline (Zoloft) and cognitive behavior therapy will experience improvement with their depression and consume less alcohol than individuals treated with a placebo and cognitive behavior therapy. This is a 12-week, random assignment, placebo-controlled, double-blind study with followup assessments 1 and 3 months after treatment.
NCT00001483 ↗	Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression	Completed	National Institute of Mental Health (NIMH)	Phase 2	1995-06-01	This study will compare the effectiveness of relatively new antidepressants which have different mechanisms of action. Buproprion (Wellbutrin) works on dopamine and the dopaminergic pathway. Sertraline (Zoloft) works as a selective serotonin reuptake inhibitor (SSRI). Venlafaxine (Effexor) works as a mixed serotonin, norepinephrine, and dopamine reuptake inhibitor. Subjects enrolled in this study will be patients diagnosed with a bipolar disorder who are presently taking medication to prevent the symptoms of the disease (prophylactic treatment), but have had breakthrough episodes of depression despite taking their medication. Patients will receive any one of the three antidepressant medications as noted above plus a placebo inactive sugar pill, in order to mask which antidepressant is being prescribed) in addition to their regular medication for bipolar disorder. All of the doses will be calculated as effective for the treatment of a unipolar major depressive disorder. The patient will continue receiving the medication for ten weeks. The effectiveness of the drug treatment will be measured by using three different scales; 1. Inventory for Depressive Symptoms - Clinicians form (IDS-C) 2. Clinical Global Impression scale(CGI-BP) 3. Life Charting Methodology (LCM) Patients who do not respond to their medication within ten weeks from the beginning of the study will be considered as non-responders and be offered the opportunity to start the study again, taking one of the two remaining medications. For example, if a patient was assigned to take Wellbutrin but it was ineffective, he/she could re-enter the study and be given either Zoloft or Effexor. Patients that do respond in the first ten weeks of the study will be eligible to continue taking the medication for one year to assess the long term effectiveness of the drug on preventing episodes of depression and to assess for any possible differential induction of mania.
NCT00004554 ↗	Sertraline for Alcohol Dependence and Depression	Completed	University of Pennsylvania	Phase 4	2000-01-01	This study will examine depressed alcoholic outpatients to assess whether combining naltrexone (Revia) and sertraline (Zoloft) will result in greater reductions in both drinking and depression over either medication alone or placebo. A secondary aim is to determine whether certain patient features will predict response to sertraline, naltrexone or the combination of the two drugs. Subjects will be randomized into treatment groups for 14 weeks. The followup phase includes two visits at 6 and 9 months after treatment.

Clinical Trial Conditions for ZOLOFT

Condition Name

Condition Name for ZOLOFT
Intervention	Trials
Depression	34
Major Depressive Disorder	19
Healthy	16
Anxiety Disorders	8

Condition MeSH

Condition MeSH for ZOLOFT
Intervention	Trials
Depression	68
Depressive Disorder	58
Disease	33
Depressive Disorder, Major	30

Clinical Trial Locations for ZOLOFT

Trials by Country

Trials by Country for ZOLOFT
Location	Trials
United States	240
Canada	18
Australia	7
Spain	4
Brazil	3

Trials by US State

Trials by US State for ZOLOFT
Location	Trials
New York	25
California	21
Pennsylvania	16
Texas	14
Massachusetts	13

Clinical Trial Progress for ZOLOFT

Clinical Trial Phase

Clinical Trial Phase for ZOLOFT
Clinical Trial Phase	Trials
Phase 4	51
Phase 3	17
Phase 2/Phase 3	5

Clinical Trial Status

Clinical Trial Status for ZOLOFT
Clinical Trial Phase	Trials
Completed	106
Terminated	16
Recruiting	8

Clinical Trial Sponsors for ZOLOFT

Sponsor Name

Sponsor Name for ZOLOFT
Sponsor	Trials
National Institute of Mental Health (NIMH)	31
Pfizer	14
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	8

Sponsor Type

Sponsor Type for ZOLOFT
Sponsor	Trials
Other	161
Industry	53
NIH	51

ZOLOFT Market Analysis and Financial Projection

Last updated: April 27, 2026

ZOLOFT (sertraline): Clinical-trials update and market analysis with projections

What is ZOLOFT and what is its current clinical-trials footprint?

ZOLOFT is the brand name for sertraline, a selective serotonin reuptake inhibitor (SSRI) used across depressive and anxiety disorders. The brand’s clinical-trials activity is now dominated by: (1) label-expansion studies (rare for this mature asset), (2) comparative and pragmatic studies, and (3) pharmacokinetic (PK), formulation, and real-world effectiveness work.

Clinical-trials update (public registry trend)

• Ongoing interventional studies: Limited and typically focused on specific populations (e.g., pediatrics subsets, geriatric cohorts, or comorbidity-defined subgroups) and observational extensions.
• Ongoing observational/real-world evidence: More frequent than new pivotal interventional programs.
• Time-to-outcome profile: Studies often use endpoints aligned with standardized symptom scales (MADRS, HAM-D, GAD-7, PHQ-9) and safety monitoring for class-relevant signals (GI effects, sexual dysfunction, suicidality screening in younger populations, serotonin syndrome risk with co-medications).

Practical implication for R&D planning For an established SSRI like sertraline, near-term “pipeline risk” is less about clinical failure and more about commercial substitution dynamics (generics, payer preferred drug lists, and formulary access) and incremental evidence generation aimed at sustaining utilization rather than changing standard of care.

No complete clinical-trials update can be produced here without a source-backed list of active trials by registry number, status, and endpoints. The public record for sertraline is broad and fragmented across trials, sponsors, and countries, and a reliable “as-of” update must be grounded in specific, citable trial records.

---

How big is the ZOLOFT market and who captures the value?

ZOLOFT is off-patent in most major jurisdictions and faces pervasive generic competition. That structure shifts value from “brand exclusivity” to brand preference (where it exists), formulary inclusion, rebates, and trust/continuity-of-care.

Market structure

• Core class competition: Other SSRIs and direct antidepressant comparators depending on country and payer policy.
• Generic dominance: Pricing and volume are strongly influenced by generic penetration and automatic substitution rules.
• Therapy adherence and switching: Sertraline benefits from clinician familiarity and broad dosing experience, but that advantage is competed away through cost-led prescribing.

Evidence that sertraline’s value is capped by generic substitution

• ZOLOFT’s current product label is maintained, but brand economics are constrained by generic availability. The FDA retains current-label information while market pricing is governed by generic supply and payer contracts.
  • FDA product labeling data exists for sertraline and ZOLOFT (see references). [1][2]

A complete market analysis with numeric shares, revenue, and volume projections requires region-specific market data (US/EU/Top5 ex-US), brand vs generic sales, and payer/formulary benchmarking that is not contained in the FDA label sources. High-stakes projections must be sourced from market-intelligence providers or audited sales datasets.

---

What projections are credible for ZOLOFT over the next 3–5 years?

For an off-patent SSRI brand, projections typically follow a pattern:

1. Baseline utilization drift with cohort-level incidence of depression/anxiety,
2. Formulaic share erosion if payer contracts continue to favor lower-cost generics,
3. Stability scenarios if ZOLOFT maintains preferred status through rebate/contracting and continued clinician continuity,
4. Downside scenarios if additional cost pressure or substitution accelerates in key formularies.

Credible projection framework (directional)

• Revenue trend: Likely range-bound to declining versus prior-year levels, driven by price pressure and mix.
• Units trend: Units usually decline slower than revenue because generic substitution can leave prescribers within the same molecule but shift brand usage.
• Margin trend: Brand margins compress with rebate pressure and wholesaler channel economics.

No numeric projection is provided here because the prompt requires market projections that must be anchored to audited sales or credible market datasets. The available FDA-label sources confirm product status and dosing/safety context but do not provide market sales or forecast inputs required for quantitative projections. [1][2]

---

What safety and regulatory signals matter commercially for sertraline/ZOLOFT?

Regulatory and safety content affects utilization through prescribing confidence and payer restrictions tied to risk management.

Key FDA label themes (high-level)

• Suicidal thoughts and behaviors monitoring in children, adolescents, and young adults.
• Serotonin syndrome risk with serotonergic co-meds.
• Bleeding risk considerations with NSAIDs/anticoagulants.
• Activation/mania risk in bipolar-spectrum patients.
• Discontinuation effects and tapering considerations.

These are well-established class-managed risks and typically do not create abrupt restrictions absent specific signal updates. FDA label text provides the controlled safety basis for clinicians. [1][2]

---

Where does value still come from for an off-patent SSRI brand like ZOLOFT?

Even when patent-driven exclusivity ends, brands can preserve value through:

• Formulary positioning (preferred status, carve-outs, and step-therapy design),
• Switch behavior (continuity in stable patients reduces forced switches),
• Patient-physician familiarity (long clinical experience reduces perceived switching risk),
• Contracting (rebate levels relative to competing generics and authorized generics).

---

Key Takeaways

• ZOLOFT is a mature, off-patent SSRI (sertraline) where clinical-trials activity typically shifts from label-changing pivots to incremental evidence and population-specific studies.
• Brand economics are structurally constrained by generic competition; near-term forecasting hinges on payer contracting, formulary access, and brand preference rather than clinical differentiation.
• FDA labeling remains the primary citable source for current safety and dosing context. [1][2]
• A numeric market analysis and 3-to-5-year projection require audited sales or market-dataset inputs not present in label sources.

---

FAQs

1. Is ZOLOFT still approved for depression and anxiety indications?
   Yes. ZOLOFT’s indications are maintained in FDA labeling for sertraline. [1][2]

2. Does ZOLOFT have active patent protection in the US?
   For high-stakes decisioning, patent status must be confirmed via assignment and patent-family records. Patent-life specifics are not established in the FDA label sources cited here.

3. What are the main FDA label safety monitoring priorities for sertraline?
   Suicidal thoughts/behaviors monitoring in younger populations, serotonin syndrome risk with serotonergic combinations, bleeding risk with interacting agents, and bipolar-spectrum activation considerations. [1][2]

4. How does generic competition typically affect ZOLOFT revenue?
   Revenue generally faces stronger downward pressure than units because brand pricing and mix are pressured by lower-cost substitution and payer contracting.

5. What market factors matter most for projecting ZOLOFT over 3 to 5 years?
   Formulary access, rebate dynamics, step-therapy implementation, and substitution behavior within SSRIs.

---

References

[1] U.S. Food and Drug Administration. Zoloft (sertraline) Prescribing Information.
[2] U.S. Food and Drug Administration. Drug Approval Reports and Labeling for Zoloft (sertraline).